FORMULATION AND DEVELOPMENT OF NOVEL CONTROL RELEASE TRANSDERMAL PATCHES of BUPRANOLOL

Transdermal drug delivery systems offer several advantages over conventional oral or parenteral routes, including improved patient compliance, sustained drug release, and reduced systemic side effects. In this study, we aimed to formulate and develop novel controlled-release transdermal patches of Bupranolol, a beta-blocker used in the management of hypertension and angina. The patches were prepared using the solvent casting method, employing hydrophilic polymers such as carboxymethyl cellulose sodium (CMC-Na) and hydroxypropyl methylcellulose (HPMC) dissolved in a solvent mixture of ethanol and distilled water. Bupranolol was incorporated into the polymer matrix along with plasticizers such as glycerin, polyvinylpyrrolidone (PVP), and polyethylene glycol 400 (PEG400) to enhance flexibility and drug release kinetics. The formulations were characterized for various parameters including particle size, surface morphology, drug loading, encapsulation efficiency, in vitro release kinetics, and skin irritation potential. The optimized formulation exhibited desirable characteristics, including sustained drug release over 24 hours, good mechanical properties, and minimal skin irritation. In conclusion, the developed transdermal patches of Bupranolol hold promise as a novel drug delivery system for the controlled release of this cardiovascular medication, offering potential benefits in terms of improved therapeutic efficacy and patient compliance.

Keywords: Transdermal patches, Controlled release, Bupranolol, Solvent casting method, Hydrophilic polymers, Chitosan, Glycerin, Polyvinylpyrrolidone (PVP).